Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.

Item
http://www.wikidata.org/entity/Q33448095
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyOutcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantationCombination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma.Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Palonosetron versus first-generation 5-hydroxytryptamine type 3 receptor antagonists for emesis prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation.Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.
P2860

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.

Item
http://www.wikidata.org/entity/Q33448095
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Three palonosetron regimens to ...... tic stem cell transplantation.
@ast
Three palonosetron regimens to ...... tic stem cell transplantation.
@en
type
label
Three palonosetron regimens to ...... tic stem cell transplantation.
@ast
Three palonosetron regimens to ...... tic stem cell transplantation.
@en
prefLabel
Three palonosetron regimens to ...... tic stem cell transplantation.
@ast
Three palonosetron regimens to ...... tic stem cell transplantation.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Three palonosetron regimens to ...... tic stem cell transplantation.
@en
P2093
P304
P31
P356
P433
P478
P577
P5875
P698